계명대학교 의학도서관 Repository

Concomitant and hybrid therapy for Helicobacter pylori infection: A randomized clinical trial

Metadata Downloads
Author(s)
Jun HeoSeong Woo JeonJin Tae JungJoong Goo KwonDong Wook LeeHyun Soo KimChang Hun YangJeong Bae ParkKyung Sik ParkKwang Bum ChoSi Hyung LeeByung Ik Jang
Keimyung Author(s)
Park, Kyung SikCho, Kwang Bum
Department
Dept. of Internal Medicine (내과학)
Journal Title
Journal of Gastroenterology & Hepatology
Issued Date
2015
Volume
30
Issue
9
Keyword
Helicobacter pyloriPeptic ulcer diseasesStomachTreatment and antimicrobial resistance
Abstract
Background and Aims: This study aimed to validate the equivalence of first-line concomitant
and hybrid regimens for Helicobacter pylori infection in an era of increasing
antibiotic resistance. The study also aimed to assess regimen compliance.
Methods: H. pylori-infected patients from six hospitals in Korea were randomly assigned
to either concomitant or hybrid regimens. The concomitant regimen consisted of 20 mg of
esomeprazole, 1 g of amoxicillin, 500 mg of clarithromycin, and 500 mg metronidazole,
twice daily for 10 days. The hybrid regimen consisted of a 5-day dual therapy (20 mg of
esomeprazole and 1 g of amoxicillin, twice daily) followed by a 5-day quadruple therapy
(20 mg of esomeprazole, 1 g of amoxicillin, 500 mg of clarithromycin, and 500 mg of
metronidazole, twice daily).
Results: Eradication rates for concomitant and hybrid therapy were 78.6% (187/238) and
78.8% (190/241) in the intention-to-treat analysis, and 89.8% (176/196) and 89.6% (181/
202) in the per protocol analysis. For both analyses, 95% confidence intervals fell within
the ± 8% equivalence margin. Adherence was better in the hybrid group (95.0%) than in the
concomitant group (90.1%), a difference that was borderline significant (P = 0.051).
Adverse event rates were higher in the concomitant group than in the hybrid group for
nausea (15.8% vs 8.8%; P = 0.028) and regurgitation (17.6% vs 10.7%; P = 0.040).
Conclusion: As compared with concomitant therapy, hybrid therapy offered similar efficacy,
better compliance, and fewer adverse events. Hybrid therapy could be a reasonable
first-line treatment option for H. pylori in areas with high antibiotics resistance.
Keimyung Author(s)(Kor)
박경식
조광범
Publisher
School of Medicine
Citation
Jun Heo et al. (2015). Concomitant and hybrid therapy for Helicobacter pylori infection: A randomized clinical trial. Journal of Gastroenterology & Hepatology, 30(9), 1361–1366. doi: 10.1111/jgh.12983
Type
Article
ISSN
0815-9319
Source
http://lps3.onlinelibrary.wiley.com.proxy.dsmc.or.kr/doi/abs/10.1111/jgh.12983
DOI
10.1111/jgh.12983
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/32927
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
공개 및 라이선스
  • 공개 구분공개
  • 엠바고Forever
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.